This trial is testing a new HIV vaccine to see if it is safe and if it causes an immune response in healthy people who do not have HIV.
11 Primary · 9 Secondary · Reporting Duration: Measured through Month 28
107 Total Participants · 8 Treatment Groups
Primary Treatment: CH505w53 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 50 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: